Common genetic variants in NEFL influence gene expression and Neuroblastoma risk

Cancer Research

Volumn 74, Issue 23, 2014, Pages 6913-6924

  Capasso, Mario ^a,b   Diskin, Sharon ^c,d   Cimmino, Flora ^a,b   Acierno, Giovanni ^a,b   Totaro, Francesca ^a   Petrosino, Giuseppe ^a   Pezone, Lucia ^b   Diamond, Maura ^c   McDaniel, Lee ^d,e   Hakonarson, Hakon ^c,d   Iolascon, Achille ^a,b   Devoto, Marcella ^c,d,f   Maris, John M ^c,d,e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; BIOINFORMATICS; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CASE CONTROL STUDY; CELL ANCHORAGE; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; EEF1A GENE; EEF2 GENE; GENE; GENE CONTROL; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GNB2 GENE; HERITABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MYCN GENE; NEFL GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; OVERALL SURVIVAL; PRDX2 GENE; RISK ASSESSMENT; SCG2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR DIFFERENTIATION; VBP1 GENE; BIOSYNTHESIS; CELL LINE; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETICS; HEK293 CELL LINE; METABOLISM; PROCEDURES; RISK;

ALLELES; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEK293 CELLS; HUMANS; NEUROBLASTOMA; NEUROFILAMENT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84917706488     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0431     Document Type: Article

References (49)

1. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11.
2. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5.
3. Capasso M, Diskin SJ. Genetics and genomics of neuroblastoma. Cancer Treat Res 2010;155:65-84.
4. Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008;358:2585-93.
5. Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, et al.Common variations in BARD1 influence susceptibility to highrisk neuroblastoma. Nat Genet 2009;41:718-23.
6. Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 2011;469:216-20.
7. Nguyen le B, Diskin SJ, Capasso M, Wang K, Diamond MA, Glessner J, et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet 2011;7:e1002026.
8. Diskin SJ, Capasso M, Schnepp RW, Cole KA, Attiyeh EF, Hou C, et al. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet 2012;44:1126-30.
9. Capasso M, Diskin SJ, Totaro F, Longo L, De Mariano M, Russo R, et al. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis 2013;34:605-11.
10. Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: A review of statistical methods and recommendations for their application. Am J Hum Genet 2010;86:6-22.
11. Cimmino F, Spano D, Capasso M, Zambrano N, Russo R, Zollo M, et al. Comparative proteomic expression profile in all-trans retinoic acid differentiated neuroblastoma cell line. J Proteome Res 2007;6: 2550-64.
12. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13:397-411.
13. Mao L, Ding J, Zha Y, Yang L, McCarthy BA, King W, et al. HOXC9 links cell-cycle exit and neuronal differentiation and is a prognostic marker in neuroblastoma. Cancer Res 2011;71:4314-24.
14. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012; 483:589-93.
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am J Hum Genet 2007;81:559-75.
16. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. Nat Methods 2013;10:5-6.
17. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009;5:e1000529.
18. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007;39:906-13.
19. Willer CJ, Li Y, Abecasis GR. METAL: fast and effi cient meta-analysis of genomewide association scans. Bioinformatics 2010;26:2190-1.
20. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008;24:2938-9.
21. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
22. Capasso M, Avvisati RA, Piscopo C, Laforgia N, Raimondi F, de Angelis F, et al. Cytokine gene polymorphisms in Italian preterm infants: association between interleukin-10 -1082 G/A polymorphism and respiratory distress syndrome. Pediatr Res 2007;61:313-7.
23. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009;37:W600-5.
24. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012;40:D930-4.
25. Negrini S, Prada I, D'Alessandro R, Meldolesi J. REST: an oncogene or a tumor suppressor? Trends Cell Biol 2013;23:289-95.
26. Singh A, Rokes C, Gireud M, Fletcher S, Baumgartner J, Fuller G, et al. Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF(beta-TRCP) in neuroblastoma cells. Cancer 2011;117:5189-202.
27. Leermakers FA, Zhulina EB. How the projection domains of NF-L and alpha-internexin determine the conformations of NF-M and NF-H in neurofilaments. Eur Biophys J 2010;39:1323-34.
28. Gentil BJ, Cooper L. Molecular basis of axonal dysfunction and traffic impairments in CMT. Brain Res Bull 2012;88:444-53.
29. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53:3869-73.
30. MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R. Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosomes Cancer 1994;10: 151-9.
31. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, et al. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 1995;11:2121-6.
32. Trapman J, Sleddens HF, van der Weiden MM, Dinjens WN, Konig JJ, Schroder FH, et al. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 1994;54:6061-4.
33. Seitz S, Werner S, Fischer J, Nothnagel A, Schlag PM, Scherneck S. Refined deletion mapping in sporadic breast cancer at chromosomal region 8p12-p21 and association with clinicopathological parameters. Eur J Cancer 2000;36:1507-13.
34. Yaremko ML, Kutza C, Lyzak J, Mick R, Recant WM, Westbrook CA. Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast cancer. Genes Chromosomes Cancer 1996;16:189-95.
35. Yaremko ML, Recant WM,Westbrook CA. Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chromosomes Cancer 1995;13:186-91.
36. Yaremko ML, Wasylyshyn ML, Paulus KL, Michelassi F, Westbrook CA. Deletion mapping reveals two regions of chromosome 8 allele loss in colorectal carcinomas. Genes Chromosomes Cancer 1994;10:1-6.
37. Lerebours F, Olschwang S, Thuille B, Schmitz A, Fouchet P, Laurent-Puig P, et al. Deletion mapping of the tumor suppressor locus involved in colorectal cancer on chromosome band 8p21. Genes Chromosomes Cancer 1999;25:147-53.
38. Becker SA, Zhou YZ, Slagle BL. Frequent loss of chromosome 8p in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 1996;56:5092-7.
39. Coon SW, Savera AT, Zarbo RJ, Benninger MS, Chase GA, Rybicki BA, et al. Prognostic implications of loss of heterozygosity at 8p21 and 9p21 in head and neck squamous cell carcinoma. Int J Cancer 2004;111:206-12.
40. el-Naggar AK, Hurr K, Batsakis JG, Luna MA, Goepfert H, Huff V. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 1995;55:2656-9.
41. Chen B, Chen J, House MG, Cullen KJ, Nephew KP, Guo Z. Role of neurofilament light polypeptide in head and neck cancer chemoresistance. Mol Cancer Res 2012;10:305-15.
42. Huang Z, Zhuo Y, Shen Z, Wang Y, Wang L, Li H, et al. The role of NEFL in cell growth and invasion in head and neck squamous cell carcinoma cell lines. J Oral Pathol Med 2014;43:191-8.
43. Pei D, Luther W, Wang W, Paw BH, Stewart RA, George RE. Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. PLoS Genet 2013;9: e1003533.
44. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, et al. CpG island hypermethylation in human astrocytomas. CancerRes 2010;70:2718-27.
45. Balastik M, Ferraguti F, Pires-da Silva A, Lee TH, Alvarez-Bolado G, Lu KP, et al. Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration. Proc Natl Acad Sci U S A 2008;105:12016-21.
46. Munirajan AK, Ando K, Mukai A, Takahashi M, Suenaga Y, Ohira M, et al. KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. J Biol Chem 2008;283:24426-34.
47. Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 2008;22:884-93.
48. Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, Norris G, et al. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res 2012;72:2068-78.
49. Manolio TA. Bringing genome-wide association findings into clinical use. Nat Rev Genet 2013;14:549-58.